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sponse occurred in 47%. Response was evaluated, before SCT, by
PET scan and Gallium scan in 68 and 147 pts, respectively.
Fifty-one percent of the pts were in complete response (CR) or
unconﬁrmed complete response (CRu), 41% were in partial re-
sponse (PR), and 7% were stable or progressive by CT scan. PET
scan and Gallium scan were positive in 25 of 68 (37%) and 43 of
147 (29%) pts, respectively. Relapses occurred in 44 of 122 (36%)
pts. FI were positive in only 5% of the pts in CR or Cru; in contrast
FI were positive in 54% of pts in PR and in almost all patients with
progressive disease. At 3 years, the cumulative probability of PFS
was 65% for pts with a negative FI versus 22% for pts with a
positive FI (P  .0001). The 3 years OS were 94% and 73% (P 
.001) for pts with positive FI and pts with negative FI, respectively.
The 3 years PFS for pts in PR with negative FI (51%) was similar
to patients in CR (71%) (P  .188) while the 3 PFS for pts in PR
with positive FI was worse (51%) (P  .0001). The 3 years OS was
similar. In a multivariate model, positive FI affected independently
the PFS and the OS. Pre-transplant functional imaging status
predicts outcome in patients with relapsed/refractory HL. Positive
pre-SCT FI confer a poor prognosis, independent of other tradi-
tional pre-salvage prognostic factors. Patients in PR with positive
FI should be offered innovative approaches other than conven-
tional ASCT.
328
A 15-YEAR REVIEW OF AUTOLOGOUS STEM CELL TRANSPLANT OF
ADVANCED RELAPSED FOLLICULAR LYMPHOMA AT THE OTTAWA
HOSPITAL
Sabloff, M.1, McDiarmid, S.1, Atkins, H.1, Bence-Bruckler, I.1,
Bredeson, C.1, Hopkins, H.1, Genest, P.1, Perry, G.1, Huebsch, L.1
Ottawa Hospital, Ottawa, ON, Canada.
Introduction: Follicular lymphoma (FL) is regarded as an in-
curable disease and no single treatment has been shown to have a
signiﬁcant impact on overall survival during its relapsing/remitting
phase. Autologous stem cell transplantation has been investigated
with regard to whether such intensive treatment may have a more
signiﬁcant impact on the disease course. Methods: We completed
a retrospective review of a cohort of 139 unpurged autologous stem
cell transplants at the Ottawa Hospital for relapsed, advanced FL
over a period of 10 years with follow-up to the end of 2003. One
hundred seventeen of these transplants were for relapsed non-
transformed FL. The conditioning regimen consisted of Melpha-
lan (140 mg/m2), VP-16 (60 mg/m2), and total body irradiation
(500 or 1200 cGy). A minimum of 2.5 106 CD34 cells/Kg were
collected and infused. Results: The median age of the cohort was
48 years. The median follow-up was 5.6 years. The majority had
FL grade I and 53% were treated in ﬁrst relapse. The estimated
progression-free survival (PFS) was 47% and overall survival (OS)
was 51% at 10 years for all patients. The 5 year PFS of 58% for
patient with non-transformed FL was much better than the 27% 5
year PFS for patients with transformed FL. There was a trend
toward a better 5 year OS for the patients who underwent trans-
plantation for non-transformed FL (71% vs 61%). Relapse oc-
curred in 42 (36%) patients. Within the non-transformed group,
there were a total of 46 deaths (40%), 3 (3%) due to regimen
related toxicity and 9 (7%) due to secondary cancer. The median
survival from diagnosis was 16 years. In a multivariable Cox pro-
portional hazards model, age, a higher TBI dose, sensitivity to
salvage chemotherapy, and lower grade histology were signiﬁcant
prognostic variables. It was also noted that although the OS didn’t
signiﬁcantly differ in those who had 1, 2, or 	2 prior chemother-
apies, their PFS post transplant was signiﬁcantly better than their
respective PFS prior to transplant. Conclusions: We conclude
that unpurged autologous stem cell transplantation following high
dose chemotherapy is a safe and efﬁcacious treatment for multiply
relapsed FL. This treatment may prolong survival when used at
any stage of the disease. At the meeting, a further update of the
data will be presented with follow-up to the end of 2005, extending
the follow-up to 15 years. This will also include an analysis of their
survival after relapse post transplant.
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MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION IN POOR PROGNOSIS PATIENTS WITH ADVANCED
FOLLICULAR LYMPHOMA—EFFECTIVE THERAPY IN FIRST COMPLETE
OR PARTIAL REMISSION
Papajik, T.1, Faber, E.1, Raida, L.1, Prochazka, V.1, Vondrakova, J.1,
Rozmanova, S.1, Jarosova, M.1, Indrak, K.1 Hemato-oncology Depart-
ment, University Hospital, Olomouc, Czech Republic.
Conventional chemotherapy is not curative in patients (pts) with
generalized follicular lymphoma (FL), and most of them ultimately
die from the disease, with a median survival of 8 to 10 years. The
addition of rituximab to initial combination chemotherapy (eg,
R-CVP) prolongs duration of response, but the overall results in
high-risk prognostic group are still unsatisfactory. High-dose che-
motherapy and autologous stem cell transplantation (AT) in
younger pts with accumulation of several adverse prognostic fac-
tors can improve their outcome and prolong survival. Between
1997 and 2005, a total of 22 pts (16 women, 6 men) with poor-
prognosis FL grades I and II were intensively treated (antracycline-
based therapy) at our department. Imunochemotherapy with rit-
uximab was administrated in 11 of them. Seven pts achieved
complete remission (CR) and 15 pts partial remission (PR), mostly
with a tumor reduction greater than 75%. After BEAM condition-
ing therapy, median of 8,1  106kg (range, 2,1–20,8  106/kg)
CD34 peripheral blood stem cells were reinfused. At 100 days
following AT, 18 pts were in CR and 4 pts in PR. Three pts in PR
were treated with rituximab and all achieved CR. At the time of
diagnosis, 15 pts had bcl-2/IgH PCR-positive lymphoma cells in
samples from bone marrow (BM). Fourteen pts had no PCR-
detectable lymphoma cells in BM at 100 days after AT, 1 pt cleared
lymphoma cells from BM after rituximab therapy. Five out of 22
pts (23%) relapsed/progressed after a median time of 16 months
from AT and 3 pts died from recurrent lymphoma. Seventeen pts
are still alive in CR with median follow-up of 24 months (range
3–93 months) from AT. Estimated 7 years overall survival and
event free survival rates were 73% and 70%, respectively. Myeloa-
blative chemotherapy and autologous stem cell transplantation in
poor prognosis pts with advanced follicular lymphoma can lead to
long-lasting molecular CR. The standard administration of a front-
line immunochemotherapy with rituximab can further improve the
rate of CR and clear lymphoma cells from BM and peripheral
blood before stem cells collection. Supported by IGA NC-7490
and VVZ MSM 619 895 9205 grants.
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A PILOT STUDY OF MYELOABLATIVE (MA) AUTOLOGOUS STEM CELL
(autoSCT) FOLLOWED BY REDUCED INTENSITY (RI) ALLOGENEIC
TRANSPLANTATION (AlloSCT) IN CHILDREN AND ADOLESCENTS WITH
RELAPSED HODGKIN’S DISEASE (HD) AND NON-HODGKIN’S LYM-
PHOMA (NHL)
Bradley, M.B.1, Cooney, E.1, George, D.1, Garvin, J.1, Del Toro, G.1,
Bhatia, M.1, Roman, E.1, Satwani, P.1, Militano, O.1, Cheung, Y.-K.2,
Kelly, K.1, van de Ven, C.1, Schwartz, J.4, Gewanter, R.3, Martin, P.6,
Kurtzberg, J.6, Cairo, M.S.1,4,5 1. Dept of Pediatrics, Columbia Uni-
versity, NY, NY; 2. Dept. of Biostatistics, Columbia University, NY, NY;
3. Dept. of Radiation Oncology, Columbia University, NY, NY; 4.
Pathology, Columbia University, NY, NY; 5. Medicine, Columbia Uni-
versity, NY, NY; 6. Dept of Pediatrics, Duke University, Durham, NC.
AlloSCT may be beneﬁcial to patients with relapsed/refractory
HD and NHL by providing a graft versus lymphoma effect.
Carella et al (JCO 2000) and Gutman et al (BMT 2005) demon-
strated the feasibility and success of MA AutoSCT followed by RI
AlloSCT in adults with refractory lymphoma. We investigated MA
AutoSCT followed by RI AlloSCT in children with relapsed/
refractory HD/NHL. Twelve patients entered post reinduction
therapy (3CR2PR post Ifos/Carbo/VP-16, 1PR1CR post Ifos/
Vinorelbine, 1PR post Topotecan/Ifos/Carbo, 1CR post vinorel-
bine/gemcitabine, 1PR post cytarabine/VP-16/MTX, 1PR post
cytarabine/VP-16/L-asp/prednisone, 1CR post carmustine/VP-
16/cyclophosphamide). MA: Cyclophosphamide 1500 mg/m2 
4d, carmustine 100 mg/m2  3d, VP-16 800 mg/m2  3d, 
AutoSCT. CD20 patients received Rituximab (375 mg/m2/
Poster Session II
115BB&MT
wk4) and all patients IFRT (20-30 Gy) post AutoSCT. Three
patients did not proceed onto RI AlloSCT (1 HD parental with-
drawal, 1 Burkitts PD, and 1 Burkitts too early post autoSCT) 9/12
proceeded to RI AlloSCT.. RI: Fludarabine 30 mg/m2  5d,
Busulfan 3.2 mg/kg  2d, and R ATG 2 mg/kg  4d (UCB
recipients)  AlloSCT (1 related 6/6 PBSC, 1 related 5/6 PBSC, 1
8/10 MUD, 1 5/6 UCB, 5 4/6 UCB). GVHD prophylaxis: tacroli-
mus (0.03 mg/kg CIVI) on day-1- 60 and MMF (15 mg/kg
IV/PO q12h) day 1 &luAmn;28 as previously reported (Os-
unkwo/Cairo et al BBMT 2004). Six HD (3 stage IIA, 1 stage IIB,
1 stage IIIB, 1 stage IVB) and 3 NHL ( ALCL n 1, lymphoblastic
n  1, DLBCL n  1, ) have been treated. MA AutoSCT  RI
AlloSCT were well tolerated in all patients. Median time to RI
AlloSCT after MA AutoSCT was 130 days. Median F/U is 924
days. Toxicity: grade 3 hematuria (n  1), grade 3/4 infection
without neutropenia (n  4), grade 4 infection with neutropenia
(n  2), grade 4 pulmonary ﬁbrosis (n  1), grade 4 hearing loss
(n  1), and grade 4 thrombocytopenia (n  1), grade 4 neuro-
toxicity (n  1). All patients achieved 100% donor chimerism.
GVHD: grade II-III aGVHD (2/8), cGVHD (3/8). Four of 6 HD
patients: are NED; 2 patients died; PD n  1 and cGVHD n  1.
Two of 3 NHL: are NED, 1 died of PD. There has been one death
(NRM) from infection day 632. The estimated OS at 1 year is
56.2%. In summary, MA AutoSCT followed by IFRT, targeted
monoclonal antibody therapy, and RI AlloSCT is feasible and well
tolerated in pediatric patients with relapsed HD/NHL. A larger
controlled study with longer follow up is required to determine if
this approach will reduce relapse, MDS, long-term toxicity, and
improve EFS.
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BORTEZOMIB PRIOR TO AUTOLOGOUS TRANSPLANT IN MULTIPLE
MYELOMA: EFFECTS ON MOBILIZATION, ENGRAFTMENT, AND MARK-
ERS OF IMMUNE FUNCTION
Uy, G.L.1, Peles, S.1, Fisher, N.M.1, Tomasson, M.H.1, DiPersio, J.F.1,
Vij, R.1 Washington University School of Medicine, St. Louis, MO.
To explore the potential role of bortezomib (VELCADE®) in
the frontline treatment of multiple myeloma, we conducted a study
of bortezomib administered prior to autologous transplant. The
primary objective was to determine the effects of bortezomib on
cytokine based mobilization and engraftment. Given the critical
role NF-B in lymphocyte development and survival, we also
sought to determine the effects of bortezomib on markers of
immune function. Following induction, two cycles of bortezomib
1.3 mg/m2 were administered on days 1, 4, 8, and 11 of a 21-day
treatment cycle. Peripheral blood stem cells were mobilized with
G-CSF 10 mcg/kg/day for 5 days and harvested by large volume
apheresis (20 L/day) until a minimum of 2.5  106 CD34
cells/kg were collected. High-dose melphalan 200 mg/m2 was
administered followed by autologous stem cell transplant with
GM-CSF 250 mcg/m2/day support until neutrophil engraftment.
Peripheral blood was collected at baseline (cycle 1, day 1) and after
treatment with bortezomib (cycle 2, day 18) for analysis of lym-
phocyte subsets and serum cytokines. Forty patients were enrolled
with 37 continuing on to autologous transplant. Prior to receiving
bortezomib, 20 patients had been previously treated with an an-
thracycline, 22 with thalidomide, and two patients had no induc-
tion therapy. Stem cell collection was successful in 37 of 38 patients
(97%) with the median ﬁrst collection of 4.24  106 CD34cells/
kg. Following transplant, all patients engrafted with a median time
to neutrophil engraftment (ANC  500/mm3) of 11 days (range
9-14 days) and platelet engraftment (platelet count 20,000/mm3)
of 11 days (range 9-31 days). In an intention-to-treat analysis at
100 days post-transplant, we observed a CR in 6 patients (15%), a
near CR in 10 patients (25%) and a PR in an additional 19 patients
(48%) for an overall response rate of 88%. Following treatment
with bortezomib, we observed a 38% decrease in CD56 NK cells
(P  .02) and a 26% increase in CD4/CD8 ratio (P  .0006) with
a 18% decrease in CD8 cytotoxic T-cells (P  .054). No signif-
icant changes were detected in either Th1 or Th2 serum cytokine
levels: IL-2 (P  .116), TNF-alpha (P  .854), IFN- (P  .070),
IL-4 (P  .240), IL-6 (0.236), IL-10 (0.151). We conclude that
pretransplant bortezomib does not adversely impair stem cell mo-
bilization or engraftment. Bortezomib also decreases NK and cy-
totoxic T cell subsets without measurable change in serum Th1
and Th2 cytokines.
332
IMMUNOTHERAPY WITH RITUXIMAB/INTERLEUKIN 2 (IL-2) FOLLOW-
ING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT
(ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN’S LYM-
PHOMA
Holmberg, L.A.1,2,3, Maloney, D.1,2,3, Gooley, T.1,2, Bensinger,
W.I.1,2,3 1. Fred Hutchinson Cancer Research Center, Seattle, WA; 2.
University of Washington School of Medicine, Seattle, WA; 3. Puget
Sound Oncology Consortium, Seattle, WA.
Relapse of NHL remains a problem after ASCT. Early after
ASCT, the immune system is not very active and the addition of
immunotherapy may decrease the incidence of relapse and prolong
survival. In an initial phase I/II trial at our center, the immune-
modulator IL-2 increased NK and LAK activity in vitro. Since
Rituximab can lyse CD20 cells by ADCC, adding Rituximab to
IL-2 should boost its effectiveness. From January 2000, 20 patients
with CD20 NHL received ASCT followed by Rituximab/IL-2
therapy. The pathology at the time of ASCT included: follicular
small/large cleaved (n  2), diffuse large/T cell rich B cell (n  8),
mantle cell (n  4) and transformed from indolent to diffuse (n 
6). The disease status was primary refractory (n 3), relapse 1(PR)
(n  5), remission 1 (n  3), remission 2 (n  8) and relapse
2/refractory (n  1). The median age of the patients was 46 years
(range 31-70). The median time to initiation of the therapy was 79
days after transplant (range 49-100). The treatment schema was:
IL-2 0.6 106 IU/m2/day sc times 12 weeks, followed by 1.4 106
IU/m2 sc three times/week for an additional 12 weeks (for a total
of 24 weeks of IL-2 therapy). Rituximab was given iv at 375 mg/m2
for a total of 4 doses: beginning one day prior to starting IL-2, then
between days 25-30, 50-55 and 75-80 post beginning IL-2. NCI
Common Toxicity Criteria were used to evaluate adverse events.
Most common grade 3 /4 toxicities were neutropenia (n  9),
pneumonia (n  2), hypothyroidism (n  1), hypokalemia (n  1)
and pulmonary dysfunction (decreased DLCO) (n  1). Neutro-
penia responded to G-CSF. There were 11 infectious episodes,
pneumonia (inﬂuenza n  1) and pneumococcus strept (n  1),
oral thrush (n  2), herpes simplex (n  1), urinary tract infection
(n  1), zoster (n  1) and upper respiratory infection (n  4).
Most common side effects were fatigue, ertyheyma/indurationa/
discomfort at IL-2 injection sites and ﬂu-like symptoms. Seven
patients stopped therapy before completing 24 weeks due to sub-
dural hematoma and progression of NHL (n 1), pneumonia (n
2), decreased DLCO (n  1) and at own or physician’s choice
without grade 3/4 toxicity (n  3) at 9, 13, 14.5 weeks. With a
median follow-up of 45 months (range 14-64), 18 patients remain
alive and in compete remission. The combination of IL-2/ Ritux-
imab can be administered with acceptable toxicity and has a high
response rate. A randomized trial has been initiated to address
whether this combination therapy is beneﬁcial to patients.
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HIGH RATES OF REACTIVATION OF VARICELLA ZOSTER VIRUS (VZV)
ASSOCIATED WITH BORTEZOMIB (VELCADE) WHEN GIVEN PRE AND
POST HIGH DOSE CHEMOTHERAPY (HDCT)
Peles, S.1, Uy, G.L.1, Fisher, N.M.1, Tomasson, M.H.1, DiPersio, J.F.1,
Vij, R.1 Washington University School of Medicine, St. Louis, MO.
We evaluated the tolerability and efﬁcacy of the proteasome
inhibitor bortezomib administered to multiple myeloma (MM)
patients both prior to, and as consolidation therapy following
HDCT, in a prospective pilot study. Patients received 2 cycles of
bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of every 21 days,
prior to stem cell collection and melphalan 200mg/m2, followed by
six cycles of consolidation bortezomib 1.3 mg/m2 given once
weekly for 4 of every 5 weeks, 90–120 days following transplanta-
tion. Of 40 enrolled patients, 33 have received at least one post
transplantation cycle of consolidation bortezomib. Patient and
Poster Session II
116
